Skip to main content
August 02

August 02, 2011
Bad Homburg, Germany

Conference Call Q2 2011, Fresenius

 Live Webcast

November 02

November 02, 2011
Bad Homburg, Germany

Conference Call Q3 2011, Fresenius

 

Live Webcast

 

February 21

February 21, 2012
Bad Homburg, Germany

Conference Call Full Year Results 2011, Fresenius

 

Live Webcast

May 03

May 03, 2012
Bad Homburg, Germany

Conference Call Q1 2012, Fresenius

 

Live Webcast

June 12

June 12, 2012
Bad Homburg, Germany

Capital Market Day Fresenius Kabi

July 23

July 23, 2012
Bad Homburg, Germany

Acquisition of Fenwal Holdings, Inc.

 

Live Webcast

August 01

August 01, 2012
Bad Homburg, Germany

Conference Call Q2 2012, Fresenius

 Live Webcast

 

October 31

October 31, 2012
Bad Homburg, Germany

Conference Call Q3 2012, Fresenius

 Live Webcast

December 03

December 03, 2015
Boca Raton, USA

Bank of America Merrill Lynch – Leveraged Finance Conference

December 2 – 4, 2015

 

Moody’s Investors Service has upgraded the corporate credit rating of Fresenius from Ba1 to Baa3 with a stable outlook.

The upgrade reflects Moody's view that Fresenius' business profile has improved over the last years supported by higher business and geographical diversification and increased scale as well as a strong track record of profitable growth and deleveraging post acquisitions.

In January 2015, Standard & Poor’s upgraded the corporate credit rating of Fresenius from previously BB+ to BBB- with a stable outlook.

Fresenius continues to view itself as an active consolidator in its markets and will continue to focus on financing acquisitions primarily with debt.

 

 

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Subscribe to